Tianshu J. Liu

No. 180 Fenglin Road
Xuhui, 200032, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 308 publications

Matching-adjusted indirect comparison of fruquintinib versus ramucirumab in advanced gastric or gastroesophageal junction adenocarcinoma.

Matching-adjusted indirect comparison of fruquintinib versus ramucirumab in advanced gastric or gastroesophageal junction adenocarcinoma.

Journal: Journal of comparative effectiveness research

Published: August 12, 2026

Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer.

Zanidatamab with and without Tislelizumab in HER2-Positive Gastroesophageal Cancer.

Journal: The New England journal of medicine

Published: May 27, 2026

A clinico-radiological model integrating baseline CT-derived body composition to predict prognosis in immunotherapy-treated metastatic colorectal cancer.

A clinico-radiological model integrating baseline CT-derived body composition to predict prognosis in immunotherapy-treated metastatic colorectal cancer.

Journal: European journal of radiology

Published: April 21, 2026

Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.

Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.

Journal: Nature medicine

Published: April 17, 2026

Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2-Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial.

Trastuzumab Rezetecan in Human Epidermal Growth Factor Receptor 2-Expressing Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: A Multicenter, Open-Label, Phase I Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 04, 2026

Chinese guidelines for HER2-targeted therapy in gastric and gastroesophageal junction adenocarcinoma (2025 Edition).

Chinese guidelines for HER2-targeted therapy in gastric and gastroesophageal junction adenocarcinoma (2025 Edition).

Journal: Journal of hematology & oncology

Published: February 02, 2026

NLRC3 in septic immunosuppression: Variation in expression and mechanisms of mediating immune cell dysfunction (Review).

NLRC3 in septic immunosuppression: Variation in expression and mechanisms of mediating immune cell dysfunction (Review).

Journal: Experimental and therapeutic medicine

Published: December 18, 2025

Genomic analysis of oesophageal carcinoma (EC) identifies recurrent mutations in histone methyltransferases as a distinctive subset.

Genomic analysis of oesophageal carcinoma (EC) identifies recurrent mutations in histone methyltransferases as a distinctive subset.

Journal: Oncogene

Published: November 05, 2025

Study of the Magnetic Dipole Transition of J/ψ→γη_{c} via η_{c}→pp[over ¯].

Study of the Magnetic Dipole Transition of J/ψ→γη_{c} via η_{c}→pp[over ¯].

Journal: Physical review letters

Published: October 17, 2025

First Measurement of the D_{s}^{+}→K^{0}μ^{+}ν_{μ} Decay.

First Measurement of the D_{s}^{+}→K^{0}μ^{+}ν_{μ} Decay.

Journal: Physical review letters

Published: October 08, 2025

Camrelizumab Plus Famitinib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Study.

Camrelizumab Plus Famitinib in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Study.

Journal: Cancer medicine

Published: September 17, 2025

Chinese consensus on first-line precision therapy for advanced gastric cancer.

Chinese consensus on first-line precision therapy for advanced gastric cancer.

Journal: Innovation (Cambridge (Mass.))

Published: September 16, 2025

Showing 1-12 of 308

Last Updated: 09/26/2026